Antiviral properties of two trimeric recombinant gp41 proteins

Retrovirology

Volumn 3, Issue , 2006, Pages

  Delcroix Genête, Delphine ^a,b   Quan, Phenix Lan ^a,b,c   Roger, Marie Gaëlle ^d   Hazan, Uriel ^a,b,e   Nisole, Sébastien ^a,b,e   Rousseau, Cécile ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c Mymetics Corporation   (Switzerland)

^d Protein'eXpert SA   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MEMBRANE PROTEIN; RECOMBINANT GLYCOPROTEIN GP 41A; RECOMBINANT GLYCOPROTEIN GP 41B; UNCLASSIFIED DRUG; VIRUS RECEPTOR; GAG PROTEIN; GLYCOPROTEIN GP 41; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHILICITY; PROMOTER REGION; PROTEIN DOMAIN; STRUCTURE ANALYSIS; T LYMPHOCYTE; TARGET CELL; VIRUS ENVELOPE; VIRUS ISOLATION; BLOOD; CELL FUSION; CELL LINE; CHEMISTRY; GENE DELETION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; KIDNEY; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; PLASMID; REPORTER GENE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL AGENTS; CELL FUSION; CELL LINE; GENE DELETION; GENE PRODUCTS, ENV; GENES, REPORTER; HELA CELLS; HIV; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; KIDNEY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; PLASMIDS; RECOMBINANT PROTEINS; VIRUS REPLICATION;

EID: 33645774712     PISSN: 17424690     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-3-16     Document Type: Article

References (49)

1. Moore JP, Stevenson M: New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol 2000, 1(1):40-49.
2. Fauci AS: HIV and AIDS: 20 years of science. Nat Med 2003, 9(7):839-843.
3. Chun TW, Davey RT, Engel D, Lane HC, Fauci AS: Re-emergence of HIV after stopping therapy. Nature 1999, 401(6756):874-875.
4. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF: Latent infection of CD4(+) T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine 1999, 5(5):512-517.
5. Pomerantz RJ: Eliminating HIV-1 reservoirs. Curr Opin Investig Drugs 2002, 3(8):1133-1137.
6. Hamer DH: Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it. Curr HIV Res 2004, 2(2):99-111.
7. Chun TW, Fauci AS: Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A 1999, 96(20):10958-10961.
8. Pierson TC, Doms RW: HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 2003, 281:1-27.
9. Wyatt R, Sodroski J: The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280(5371):1884-1888.
10. Altmeyer R: Virus attachment and entry offer numerous targets for antiviral therapy. Curr Pharm Des 2004, 10(30)3701-3712.
11. Clapham PR, McKnight A: Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol 2002, 83(Pt 8):1809-1829.
12. Gallaher WR: Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell 1987, 50(3):327-328.
13. Delwart EL, Mosialos G, Gilmore T: Retroviral envelope glycoproteins contain a 'leucine zipper'-like repeat. AIDS Res Hum Retroviruses 1990, 6(6):703-706.
14. Chambers P, Pringle CR, Easton AJ: Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J Gen Virol 1990, 71 (Pt 12):3075-3080.
15. Chan DC, Fass D, Berger JM, Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89(2):263-273.
16. Lu M, Blacklow SC, Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995, 2(12):1075-1082.
17. Tan K, Liu J, Wang J, Shen S, Lu M: Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 1997, 94(23):12303-12308.
18. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387(6631):426-430.
19. Eckert DM, Kim PS: Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001, 70:777-810.
20. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawatt SS, Puri A, Durell S, Blumenthal R: The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003, 1614(1):36-50.
21. Chan DC, Kim PS: HIV entry and its inhibition. Cell 1998, 93(5):681-684.
22. He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, Weng Y, Weiss CD: Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 2003, 77(3):1666-1671.
23. Rimsky LT, Shugars DC, Matthews TJ: Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998, 72(2):986-993.
24. Eckert DM, Kim PS: Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci U S A 2001, 98(20):11187-11192.
25. Root MJ, Kay MS, Kim PS: Protein design of an HIV-1 entry inhibitor. Science 2001, 291(5505):884-888.
26. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998, 4(11):1302-1307.
27. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994, 91(21):9770-9774.
28. Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D: Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004, 3(3):215-225.
29. Kliger Y, Shai Y: Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J Mol Biol 2000, 295(2):163-168.
30. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002, 46(6):1896-1905.
31. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E: Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000, 74(18):8358-8367.
32. Derdeyn CA, Decker JM, Sfakianos JN, Zhang Z, O'Brien WA, Ratner L, Shaw GM, Hunter E: Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001, 75(18):8605-8614.
33. Yuan W, Craig S, Si Z, Farzan M, Sodroski J: CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol 2004, 78(10):5448-5457.
34. Moore JP, McKeating JA, Weiss RA, Sattentau QJ: Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990, 250(4984):1139-1142.
35. Hart TK, Kirsh R, Ellens H, Sweet RW, Lambert DM, Petteway SRJ, Leary J, Bugelski PJ: Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc Natl Acad Sci U S A 1991, 88(6):2189-2193.
36. Sattentau QJ, Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991, 174(2):407-415.
37. Bar S, Alizon M: Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. J Virol 2004, 78(2):811-820.
38. Furuta RA, Wild CT, Weng Y, Weiss CD: Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998, 5(4):276-279.
39. Lu M, Ji H, Shen S: Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion. J Virol 1999, 73(5):4433-4438.
40. Ji H, Shu W, Burling FT, Jiang S, Lu M: Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol 1999, 73(10):8578-8586.
41. Ghorpade A, Xia MQ, Hyman BT, Persidsky Y, Nukuna A, Bock P, Che M, Limoges J, Gendelman HE, Mackay CR: Role of the beta-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia. J Virol 1998, 72(4):3351-3361.
42. Nisole S, Krust B, Callebaut C, Guichard G, Muller S, Briand JP, Hovanessian AG: The anti-HIV pseudopeptide HB-19 forms a complex with the cell-surface-expressed nucleolin independent of heparan sulfate proteoglycans. J Biol Chem 1999, 274(39):27875-27884.
43. Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S: Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005, 280(12):11259-11273.
44. Kliger Y, Gallo SA, Peisajovich SG, Munoz-Barroso I, Avkin S, Blumenthal R, Shai Y: Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J Biol Chem 2001, 276(2):1391-1397.
45. Munoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R: Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 1998, 140(2):315-323.
46. Markosyan RM, Cohen FS, Melikyan GB: HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell 2003, 14(3):926-938.
47. Louis JM, Bewley CA, Clore GM: Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem 2001, 276(31):29485-29489.
48. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. In J Exp Med Volume 185. Issue 4 1114 First Ave, 4TH Fl, New York, NY 10021, Rockefeller Univ Press; 1997:621-628.
49. Dumonceaux J, Nisole S, Chanel C, Quivet L, Amara A, Baleux F, Briand P, Hazan U: Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J Virol 1998, 72(1):512-519.